Is there a future for interleukin 17 blocking agents in Rheumatoid arthritis?

Journal of Rheumatology

Volumn 43, Issue 3, 2016, Pages 465-467

  Durez, Patrick ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL MARKER; BRODALUMAB; C REACTIVE PROTEIN; CANAKINUMAB; INTERLEUKIN 17; INTERLEUKIN 23; IXEKIZUMAB; METHOTREXATE; PLACEBO; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL EFFECTIVENESS; DAS28; DISEASE COURSE; DISEASE MARKER; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDITORIAL; GENE EXPRESSION PROFILING; HUMAN; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; TH17 CELL; TREATMENT RESPONSE; ANIMAL; IMMUNOLOGY; INFLAMMATION;

ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; INTERLEUKIN-17;

EID: 84959924974     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.160010     Document Type: Editorial

References (20)

1. Benedetti G, Miossec P. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol 2014;44:339-47.
2. Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. J Rheumatol 2014;41:629-39.
3. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005;7:29-37.
4. Tlustochowicz W, Rahman P, Seriolo B, Krammer G, Porter B, Widmer A, et al. Efficacy and safety of subcutaneous and intravenous loading dose regimens of secukinumab in patients with active rheumatoid arthritis: results from a randomized phase II study. J Rheumatol 2016;43:495-503.
5. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013;72:863-9.
6. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, et al. One year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomised, placebo-controlled study. J Rheumatol 2014;41:414-21.
7. Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 2014;66:1693-704.
8. Pavelka K, Chon Y, Newmark R, Lin SL, Baumgartner S, Erondu N. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol 2015;42:912-9.
9. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich H, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90.
10. Alten R, Gomez-Reino J, Durez P, Beaulieu A, Sebba A, Krammer G, et al. Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Muskuloskelet Disord 2011;12:153.
11. Burmester GR, Durez P, Shestakova G, Genovese MC, Schulze-Koops H, Li Y, et al. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Rheumatology 2016;55:49-55.
12. Cuppen BV, Welsing PM, Sprengers JJ, Bijlsma JW, Marijnissen AC, van Laar JM, et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology 2015;pii:kev421.
13. Lauwerys B, Hernandez-Lobato D, Gramme P, Ducreux J, Dessy A, Focant I, et al. Heterogeneity of synovial molecular patterns in patients with arthritis. PLoS One 2015;10:e0122104.
14. Van Baarsen LG, Lebre MC, van der Coelen D, Aarrass S, Tang MW, Ramwadhdoebe TH, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther 2014;16:426.
15. Kenna TJ, Davidson SI, Duan R, Bradbury LA, McFarlane J, Smith M, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis. Arthritis Rheum 2012;64:1420-9.
16. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015;373:2534-48.
17. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015;373:1329-39.
18. Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510-6.
19. Van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes MW, et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011;63:73-83.
20. U.S. Department of Health and Human Services. Guidance for industry rheumatoid arthritis: developing drug products for treatment. 2013. [Internet. Accessed January 6, 2016.] Available from: www.fda.gov/downloads/Drugs/GuidanceCompliance Regulatory Information/Guidances/UCM354468.pdf